Results 91 to 100 of about 3,108,169 (356)

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy

Cells, 2021
The blockade of programmed cell death protein 1 (PD-1) as monotherapy has been widely used in melanoma, but to identify melanoma patients with survival benefit from anti-PD-1 monotherapy is still a big challenge.
Jian-Guo Zhou, Bo Liang, Jian-Guo Liu, Su-Han Jin, Si-Si He, Benjamin Frey, Ning Gu, Rainer Fietkau, Markus Hecht, Hu Ma, Udo S. Gaipl   +10 more
doaj   +1 more source

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. [PDF]

, 2020
PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.
Algazi, Alain P, Andtbacka, Robert HI, Arlauckas, Sean P, Ballesteros-Merino, Carmen, Bannavong, Donna, Bhatia, Shailender, Bifulco, Carlos, Browning, Erica, Canton, David A, Daud, Adil I, Fong, Lawrence, Fox, Bernard A, Francisco, Murray, Gargosky, Sharron, Garris, Christopher, Hermiz, Reneta, Le, Mai, Levine, Lauren P, Oglesby, Arielle, Pierce, Robert, Pittet, Mikael J, Rosenblum, Michael D, Tsai, Katy K, Twitty, Christopher G   +23 more
core   +2 more sources

Ipilimumab for advanced metastatic melanoma [PDF]

Expert Opinion on Biological Therapy, 2012
The June issue of Expert Opinion on Biological Therapy (EOBT) contains a review article entitled ‘Ipilimumab in the Treatment of Melanoma’ [1]. I highly recommend this excellent paper to all colleagues interested in the treatment of patients with metastatic melanoma, because it provides detailed information without neglecting open questions in a field ...
openaire   +2 more sources

Advances in immunotherapy for melanoma [PDF]

Melanoma Management, 2014
Paolo A Ascierto obtained his MD from the University of Naples, Italy, where he earned board certification in oncology. He is currently Director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, National Tumor Institute 'Fondazione G. Pascale', Naples, Italy. Before his present position, he served consecutive positions there as
Paolo A, Ascierto, James, Larkin
openaire   +2 more sources

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. [PDF]

, 2017
Uveal melanoma is the most common primary intraocular malignant tumor in adults and arises from the transformation of melanocytes in the uveal tract. Even after treatment of the primary tumor, up to 50% of patients succumb to metastatic disease.
Aplin, Andrew E., Benovic, Jeffrey L., Chua, Vivian, Lapadula, Dominic, Randolph, Clinita, Wedegaertner, Philip B.   +5 more
core   +1 more source

Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells

FEBS Open Bio, EarlyView.
This study explores the feasibility of expressing the antitumoral protein Amblyomin‐X through a suicide gene therapy approach and investigates its intracellular fate after gene delivery. Although the gene is efficiently expressed, melanoma cells rapidly degrade the Amblyomin‐X protein via proteasome activity.
Victor Dal Posolo Cinel, Carlos DeOcesano Pereira, Aline Ramos Maia Lobba, Melissa Regina Fessel, Ana Marisa Chudzinski‐Tavassi   +4 more
wiley   +1 more source

Disparities in melanoma Breslow thickness at diagnosis in north-east London

Clinical Medicine
Background: International studies have observed inequalities in the stage of diagnosis of melanoma.1–5 Given that this has not been sufficiently studied in the UK, the purpose of this study was to investigate whether there are age-related, gender and ...
Yik Ting Chan
doaj   +1 more source

Low Vitamin D Status Predicts Poor Clinical Outcome in Advanced Melanoma Treated With Immune Checkpoint or BRAF/MEK Inhibitors: A Prospective Non-Interventional Side-by-Side Analysis

Frontiers in Oncology, 2022
In melanoma and other malignancies, low vitamin D status is associated with increased risk and poor prognosis. However, there are limited data of the impact of 25(OH)D serum concentration (s.c.) on clinical outcome in advanced melanoma.
Jörg Reichrath, Florian Biersack, Stefan Wagenpfeil, Jakob Schöpe, Claudia Pföhler, Roman Saternus, Thomas Vogt   +6 more
doaj   +1 more source